Procaterol
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Procaterol
Description:
Procaterol is an oral selective β2 adrenergic receptor agonist. Procaterol inhibits eosinophil migration and the release of eosinophil chemotactic factor from BEAS-2B cells through a cyclic AMP-dependent mechanism. Procaterol has a large dose difference existing between the bronchodilator effect and the anabolic effect in rat, can be used for asthma research in athletes[1].UNSPSC:
12352005Hazard Statement:
H302-H312-H332Target:
Adrenergic ReceptorType:
Reference compoundRelated Pathways:
GPCR/G Protein; Neuronal SignalingApplications:
Neuroscience-NeuromodulationField of Research:
OthersAssay Protocol:
https://www.medchemexpress.com/procaterol.htmlSolubility:
10 mM in DMSOSmiles:
O[C@@H](C(C=C1)=C(C=CC2=O)C(N2)=C1O)[C@@H](CC)NC(C)CMolecular Formula:
C16H22N2O3Molecular Weight:
290.36Precautions:
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501References & Citations:
[1]Ikezono K, et al. Bronchodilating effect and anabolic effect of inhaled procaterol. Int J Sports Med. 2008 Nov;29 (11) :888-94. |[2]Tashimo H, et al. Effect of procaterol, a beta (2) selective adrenergic receptor agonist, on airway inflammation and hyperresponsiveness. Allergol Int. 2007 Sep;56 (3) :241-7. |[3]Koyama S, et al. Procaterol inhibits IL-1beta- and TNF-alpha-mediated epithelial cell eosinophil chemotactic activity. Eur Respir J. 1999 Oct;14 (4) :767-75. |[4]Yamaya M, et al. Procaterol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Eur J Pharmacol. 2011 Jan 10;650 (1) :431-44. |[5]Komatani-Tamiya N, et al. Procaterol-stimulated increases in ciliary bend amplitude and ciliary beat frequency in mouse bronchioles. Cell Physiol Biochem. 2012;29 (3-4) :511-22.Shipping Conditions:
Room temperatureScientific Category:
Reference compound1Clinical Information:
Phase 4Isoform:
β adrenergic receptorCAS Number:
[72332-33-3]
